Risk factors associated with antineoplastic chemotherapy-induced nausea and vomiting
Autor(a) principal: | |
---|---|
Data de Publicação: | 2020 |
Outros Autores: | , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Revista de Saúde Pública |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0034-89102020000100282 |
Resumo: | ABSTRACT OBJECTIVE: To estimate the incidence and to evaluate risk factors for antineoplastic nausea and vomiting with high and moderate emetogenic chemotherapy in adult patients in the first treatment cycle. METHODS: Prospective cohort study with follow-up of 269 adults during the first cycle of antineoplastic chemotherapy. The incidence of nausea and vomiting was evaluated in the acute phase (0–24 hours), in the late phase (24 hours–5th day) and in the total phase (0–5th day). RESULTS: In total, 152 patients underwent high emetogenic chemotherapy and 117 moderate emetogenic chemotherapy. The relative frequency of nausea was higher when compared with vomiting in the acute phase (p < 0.001) and in the late phase (p < 0.001). The risk factors identified were: age group ≤ 49 years (odds ratio = 0.47; 95%CI 0.23–0.95) and 50–64 years (odds ratio = 0.45; 95%CI 0.23–0.87), tobacco use (odds ratio = 0.35; 95%CI 0.14–0.88), and high emetogenic chemotherapy (odds ratio 0.55; 95%CI 0.31–0.95). CONCLUSION: The incidence of nausea was higher than that of vomiting, and adverse effects were more frequent in the late phase. The results suggest the risk factors for chemotherapy-induced nausea and vomiting are tobacco, age (young adults), and high emetogenic chemotherapy. |
id |
USP-23_e5e92ce5585ae5ef94ba73baf5dd23fb |
---|---|
oai_identifier_str |
oai:scielo:S0034-89102020000100282 |
network_acronym_str |
USP-23 |
network_name_str |
Revista de Saúde Pública |
repository_id_str |
|
spelling |
Risk factors associated with antineoplastic chemotherapy-induced nausea and vomitingAntineoplastic, adverse effectsNausea Vomiting, prevention and control AntiemeticsNeoplasias, therapyCohort studiesABSTRACT OBJECTIVE: To estimate the incidence and to evaluate risk factors for antineoplastic nausea and vomiting with high and moderate emetogenic chemotherapy in adult patients in the first treatment cycle. METHODS: Prospective cohort study with follow-up of 269 adults during the first cycle of antineoplastic chemotherapy. The incidence of nausea and vomiting was evaluated in the acute phase (0–24 hours), in the late phase (24 hours–5th day) and in the total phase (0–5th day). RESULTS: In total, 152 patients underwent high emetogenic chemotherapy and 117 moderate emetogenic chemotherapy. The relative frequency of nausea was higher when compared with vomiting in the acute phase (p < 0.001) and in the late phase (p < 0.001). The risk factors identified were: age group ≤ 49 years (odds ratio = 0.47; 95%CI 0.23–0.95) and 50–64 years (odds ratio = 0.45; 95%CI 0.23–0.87), tobacco use (odds ratio = 0.35; 95%CI 0.14–0.88), and high emetogenic chemotherapy (odds ratio 0.55; 95%CI 0.31–0.95). CONCLUSION: The incidence of nausea was higher than that of vomiting, and adverse effects were more frequent in the late phase. The results suggest the risk factors for chemotherapy-induced nausea and vomiting are tobacco, age (young adults), and high emetogenic chemotherapy.Faculdade de Saúde Pública da Universidade de São Paulo2020-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0034-89102020000100282Revista de Saúde Pública v.54 2020reponame:Revista de Saúde Públicainstname:Universidade de São Paulo (USP)instacron:USP10.11606/s1518-8787.2020054002178info:eu-repo/semantics/openAccessSimino,Giovana Paula RezendeReis,Ilka AfonsoAcurcio,Francisco de AssisAndrade,Eli Iola GurgelBrazil,Natalia Maria LinharesCherchiglia,Mariângela Lealeng2020-11-06T00:00:00Zoai:scielo:S0034-89102020000100282Revistahttp://www.scielo.br/scielo.php?script=sci_serial&pid=0034-8910&lng=pt&nrm=isoONGhttps://old.scielo.br/oai/scielo-oai.phprevsp@org.usp.br||revsp1@usp.br1518-87870034-8910opendoar:2020-11-06T00:00Revista de Saúde Pública - Universidade de São Paulo (USP)false |
dc.title.none.fl_str_mv |
Risk factors associated with antineoplastic chemotherapy-induced nausea and vomiting |
title |
Risk factors associated with antineoplastic chemotherapy-induced nausea and vomiting |
spellingShingle |
Risk factors associated with antineoplastic chemotherapy-induced nausea and vomiting Simino,Giovana Paula Rezende Antineoplastic, adverse effects Nausea Vomiting, prevention and control Antiemetics Neoplasias, therapy Cohort studies |
title_short |
Risk factors associated with antineoplastic chemotherapy-induced nausea and vomiting |
title_full |
Risk factors associated with antineoplastic chemotherapy-induced nausea and vomiting |
title_fullStr |
Risk factors associated with antineoplastic chemotherapy-induced nausea and vomiting |
title_full_unstemmed |
Risk factors associated with antineoplastic chemotherapy-induced nausea and vomiting |
title_sort |
Risk factors associated with antineoplastic chemotherapy-induced nausea and vomiting |
author |
Simino,Giovana Paula Rezende |
author_facet |
Simino,Giovana Paula Rezende Reis,Ilka Afonso Acurcio,Francisco de Assis Andrade,Eli Iola Gurgel Brazil,Natalia Maria Linhares Cherchiglia,Mariângela Leal |
author_role |
author |
author2 |
Reis,Ilka Afonso Acurcio,Francisco de Assis Andrade,Eli Iola Gurgel Brazil,Natalia Maria Linhares Cherchiglia,Mariângela Leal |
author2_role |
author author author author author |
dc.contributor.author.fl_str_mv |
Simino,Giovana Paula Rezende Reis,Ilka Afonso Acurcio,Francisco de Assis Andrade,Eli Iola Gurgel Brazil,Natalia Maria Linhares Cherchiglia,Mariângela Leal |
dc.subject.por.fl_str_mv |
Antineoplastic, adverse effects Nausea Vomiting, prevention and control Antiemetics Neoplasias, therapy Cohort studies |
topic |
Antineoplastic, adverse effects Nausea Vomiting, prevention and control Antiemetics Neoplasias, therapy Cohort studies |
description |
ABSTRACT OBJECTIVE: To estimate the incidence and to evaluate risk factors for antineoplastic nausea and vomiting with high and moderate emetogenic chemotherapy in adult patients in the first treatment cycle. METHODS: Prospective cohort study with follow-up of 269 adults during the first cycle of antineoplastic chemotherapy. The incidence of nausea and vomiting was evaluated in the acute phase (0–24 hours), in the late phase (24 hours–5th day) and in the total phase (0–5th day). RESULTS: In total, 152 patients underwent high emetogenic chemotherapy and 117 moderate emetogenic chemotherapy. The relative frequency of nausea was higher when compared with vomiting in the acute phase (p < 0.001) and in the late phase (p < 0.001). The risk factors identified were: age group ≤ 49 years (odds ratio = 0.47; 95%CI 0.23–0.95) and 50–64 years (odds ratio = 0.45; 95%CI 0.23–0.87), tobacco use (odds ratio = 0.35; 95%CI 0.14–0.88), and high emetogenic chemotherapy (odds ratio 0.55; 95%CI 0.31–0.95). CONCLUSION: The incidence of nausea was higher than that of vomiting, and adverse effects were more frequent in the late phase. The results suggest the risk factors for chemotherapy-induced nausea and vomiting are tobacco, age (young adults), and high emetogenic chemotherapy. |
publishDate |
2020 |
dc.date.none.fl_str_mv |
2020-01-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0034-89102020000100282 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0034-89102020000100282 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.11606/s1518-8787.2020054002178 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Faculdade de Saúde Pública da Universidade de São Paulo |
publisher.none.fl_str_mv |
Faculdade de Saúde Pública da Universidade de São Paulo |
dc.source.none.fl_str_mv |
Revista de Saúde Pública v.54 2020 reponame:Revista de Saúde Pública instname:Universidade de São Paulo (USP) instacron:USP |
instname_str |
Universidade de São Paulo (USP) |
instacron_str |
USP |
institution |
USP |
reponame_str |
Revista de Saúde Pública |
collection |
Revista de Saúde Pública |
repository.name.fl_str_mv |
Revista de Saúde Pública - Universidade de São Paulo (USP) |
repository.mail.fl_str_mv |
revsp@org.usp.br||revsp1@usp.br |
_version_ |
1748936506052968448 |